Editas Medicine Inc at JPMorgan Healthcare Conference Transcript
Good afternoon. Thanks for joining us for another session at the 42nd J.P. Morgan Healthcare Conference. I'm Brian Cheng. I'm one of the senior biotech analysts here at the firm. I'm joined by my associate, Sean Kim, who is also in the audience.
On stage, we have the team from Editas. I'll pass the mic to their CEO, Gilmore O'Neill, for a short presentation, followed by a live audience Q&A. (Conference Instructions) Gilmore, the stage is yours.
' -
Thank you very much, Brian. Good afternoon, everyone. It's great and we're very grateful to have you here as we tell you about Editas, what we have done in the past year, share an update on the data that we presented at ASH just recently for our lead clinical asset, and talk about our plans for the future into 2024.
Now, before going any further, you should know that I'm going to make forward-looking statements and the actual results may be materially different. And so we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
